Ultime notizie per P10 (NYSE:PX) Azioni

P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.

P10 Inc

PEXA GROUP LTD by PEXA GROUP LTD

LOCATION SCIENCES GRP NEW by Location Sciences Group PLC

Sorted Group Holdings PLC

PT BANK PERMATA ORD A by PT Bank Permata TBK

PHOENIX COPPER LTD by Phoenix Copper Limited

Phoenix Copper Ltd

PHOENIX COPPER LTD S/ADR by Phoenix Copper Limited

Pioneer Natural Resources Co Com

Pixie Dust Technologies, Inc. - ADS, each representing one common share

Pixie Dust Technologies Inc

Invesco Energy Exploration & Production ETF

Invesco FTSE RAFI Developed Markets ex-U.S. ETF

PHOENIX FOOTWEAR GROUP by Phoenix Footwear Group, Inc.

Phoenix Footwear Group Inc

PAX GLOBAL TECHNOLOGY LTD by Pax Global Technology Ltd

Pax Global Technology Ltd

Invesco FTSE RAFI Emerging Markets ETF

PHONEX HOLDINGS INC by PhoneX Holdings, Inc.

PhoneX Holdings Inc

INVSC FTSE RAFI EMERGING MARKETS ETF

Invesco Dorsey Wright Energy Momentum ETF

Invesco Oil & Gas Services ETF

UBS ETF MSCI PAC

Pixelworks Inc

Paxman AB

PaxMedica Inc

PHILEX MINING CORP ORD by Philex Mining Corp.

Philex Mining Corp

Pixium Vision SA

Pronexus Inc

Phoenix Plus Corp

PXP Energy Corp

Pexip Holding ASA

Phoenix Apps Inc

PIXARBIO CORPORATION by PixarBio Corporation

Pyxis Tankers Inc

INVESCO FTSE RAFI US INDX UNT ETF II

Pyxis Tankers Inc 7.75% PRF PERPETUAL USD 25 - Ser A

PHOENIX MEDIA INV NEW by PHOENIX MEDIA INVT (HOLDINGS) LTD.

Phoenix Media Investment (Holdings) Ltd

PHOENIX VEGA MEZZ LTD by PHOENIX VEGA MEZZ LTD

Poxel SA

PolarX Ltd

Praxsyn Corp

<p>UBS  analyst Adam Beatty   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Neutral and raises the price target from $10.5 to $12.</p>


News

Price Target

Analyst Ratings

UBS Maintains Neutral on P10, Raises Price Target to $12

<p>Oppenheimer  analyst Chris Kotowski   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Outperform and raises the price target from $13 to $16.</p>


Oppenheimer Maintains Outperform on P10, Raises Price Target to $16

<p>Morgan Stanley  analyst Michael Cyprys   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Equal-Weight and raises the price target from $10 to $12.</p>


Morgan Stanley Maintains Equal-Weight on P10, Raises Price Target to $12

<p>7 analysts have shared their evaluations of P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for P10, revealing an average target of $10.86, a high estimate of $12.00, and a low estimate of $9.50. This upward trend is apparent, with the current average reflecting a 10.14% increase from the previous average price target of $9.86.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728334843_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive P10. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$10.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Ken Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$9.50</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to P10. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of P10 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for P10's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into P10's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on P10 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into P10's Background</h2>
<p>P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.</p>
<h3>A Deep Dive into P10's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> P10's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>13.77%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> P10's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>9.84%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.95%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> P10's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.84%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> P10's debt-to-equity ratio is below the industry average at <strong>0.9</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Assessing P10: Insights From 7 Financial Analysts

<p>Barclays  analyst Benjamin Budish   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $11 to $12.</p>


Barclays Maintains Overweight on P10, Raises Price Target to $12

Enhanced Community Development Awarded $65M In New Markets Tax Credits Program

P10 Announces Agreement To Acquire Qualitas Funds For $63M, Establishing European Presence With $1B In Fee-Paying Assets Under Management And Over 1,300 LPs; Expected To Be Accretive To ANI Per Share In 2025

<p>UBS  analyst Adam Beatty   downgrades P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) from Buy to Neutral and raises the price target from $10 to $10.5.</p>


Downgrades

UBS Downgrades P10 to Neutral, Raises Price Target to $10.5

<p>Morgan Stanley  analyst Michael Cyprys   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Equal-Weight and raises the price target from $9 to $10.</p>


Morgan Stanley Maintains Equal-Weight on P10, Raises Price Target to $10

<p>In the latest quarter, 4 analysts provided ratings for P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.88, a high estimate of $12.00, and a low estimate of $9.50. Surpassing the previous average price target of $9.75, the current average has increased by 11.59%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1723492810_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of P10 among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ken Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>John Campbell</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$9.50</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to P10. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of P10 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for P10's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into P10's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on P10 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know P10 Better</h2>
<p>P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.</p>
<h3>Unraveling the Financial Story of P10</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, P10 showcased positive performance, achieving a revenue growth rate of <strong>15.48%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> P10's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>7.59%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.35%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> P10's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.6%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.93</strong>, P10 adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For P10

<p>JP Morgan  analyst Ken Worthington   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Neutral and raises the price target from $9.5 to $11.</p>


JP Morgan Maintains Neutral on P10, Raises Price Target to $11

<p>Stephens &amp; Co.  analyst John Campbell   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $11 to $12.</p>


Stephens & Co. Maintains Overweight on P10, Raises Price Target to $12

<p>Barclays  analyst Benjamin Budish   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and raises the price target from $9.5 to $11.</p>


Barclays Maintains Overweight on P10, Raises Price Target to $11

<p>Keefe, Bruyette &amp; Woods  analyst Kyle Voigt   reiterates P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Market Perform and raises the price target from $9 to $9.5.</p>


Reiteration

Keefe, Bruyette & Woods Reiterates Market Perform on P10, Raises Price Target to $9.5

<p>P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.20 by 20 percent. This is a 9.09 percent increase over earnings of $0.22 per share from the same period last year.  The company reported quarterly sales of $71.076 million which beat the analyst consensus estimate of $65.876 million by 7.89 percent.  This is a 13.72 percent increase over sales of $62.500 million the same period last year.</p>


Earnings

Earnings Beats

P10 Q2 2024 Adj. EPS $0.24 Beats $0.20 Estimate, Sales $71.076M Beat $65.876M Estimate

<p>Upsized Facilities Offer Financial Flexibility And Diversify Lending Syndicate With Joint Lead Arrangers JPMorgan Chase, KeyBanc Capital Markets, And Texas Capital Bank</p>


P10 Announces Amended And Restated Credit Agreement Expanding Total Credit Capacity To $500M

<p><i>Appoints Luke Sarsfield to Chairman, Effective in June</i><br /><br />&nbsp;</p>
<p><i>Improves Governance Policy Through Termination of Stockholder Rights Plan</i></p>
<p>DALLAS, May 08, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=UuabUkrqbYFZTU5KY-Owuut23Yc6iZyQAIWmxGJaelezgi3mvKhRMJLUxsDh735e6MjD4ElRQVvmF0Ji8g0ZiQ==">P10, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) (the "Company"), a leading private markets solutions provider,&nbsp;today announced several enhancements to its governance structure and policy.</p>
<p>Robert Alpert informed the P10 Board of Directors (the "Board") of his decision to step down as Executive Chairman, effective June 14, 2024, concurrent with the P10 Annual Meeting. Mr. Alpert will continue to serve on the Board as a director.</p>
<p>Additionally, the Board voted to appoint Luke Sarsfield to the role of Chairman of the Board, also effective June 14, 2024, and intends to appoint a Lead Independent Director at the P10 Annual Meeting.</p>
<p>"I want to thank Robert for his time as Executive Chair and look forward to our continued work on the Board," said Luke Sarsfield, P10 Chief Executive Officer. "Robert's role as Executive Chairman was intended to help me, and our senior team effect a successful leadership transition, and he now feels that transition is complete. He will continue to serve on the board as a director. I'm excited to step into this role as I work with our Board and management team to execute our strategic initiatives and advance alignment across our strategies."</p>
<p>The Company's Board also determined that its stockholder rights plan is no longer necessary for the preservation of federal income tax benefits and unanimously voted to terminate the rights plan effective as of the close of business on May 8, 2024.</p>
<p>The stockholder rights plan, which was previously set to expire in October 2024, was intended to help preserve the value of certain income tax assets, primarily tax net operating loss carryforwards. Stockholders do not have to take any action as a result of this termination.</p>
<p>These updates come in short succession after the previously announced appointment of Tracey Benford as an independent Class II director in April. Ms. Benford serves on the Company's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.</p>


Management

P10 Appoints Luke Sarsfield To Chairman, Effective June 14, 2024; Announces Termination Of Stockholder Rights Plan

<p>P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.19 by 10.53 percent. This is unchanged from the same period last year.  The company reported quarterly sales of $66.115 million which beat the analyst consensus estimate of $63.962 million by 3.37 percent.  This is a 15.48 percent increase over sales of $57.253 million the same period last year.</p>


P10 Q1 2024 Adj EPS $0.21 Beats $0.19 Estimate, Sales $66.115M Beat $63.962M Estimate

<p>In the latest quarter, 6 analysts provided ratings for P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.17, a high estimate of $12.00, and a low estimate of $9.00. This current average represents a 26.94% decrease from the previous average price target of $13.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1709564514_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The perception of P10 by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$11.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.50</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ken Worthington</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.50</td>
<td>$15.50</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to P10. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of P10 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of P10's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on P10 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know P10 Better</h2>
<p>P10 Inc is a multi-asset class private market solutions provider in the alternative asset management industry. Its revenue is composed of recurring management and advisory fees, with the vast majority of fees earned on committed capital.</p>
<h3>P10: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> P10 displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately <strong>17.89%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> P10's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-14.28%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> P10's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-2.15%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> P10's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-1.03%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> P10's debt-to-equity ratio is below the industry average at <strong>0.73</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


In-Depth Examination Of 6 Analyst Recommendations For P10

<p>Oppenheimer  analyst Chris Kotowski   maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Outperform and lowers the price target from $17 to $11.</p>


Oppenheimer Maintains Outperform on P10, Lowers Price Target to $11

P10 to acquire Qualitas Equity Funds

P10 Holdings ( ($PX) ) has shared an announcement. P10, Inc. has announced a definitive agreement to acquire Madrid-based Qualitas Equity Funds, br...

P10 Holdings Expands into Europe with Qualitas Acquisition

Analysts fell to the sidelines weighing in on P10 Holdings (PX – Research Report) and US Bancorp (USB – Research Report) with neutral ratings, indi...

Analysts Are Neutral on These Financial Stocks: P10 Holdings (PX), US Bancorp (USB)

The latest announcement is out from P10 Holdings ( ($PX) ). P10, Inc., a leader in private markets solutions, is hosting an Investor Day in New Yor...

P10 Holdings Hosts Investor Day to Discuss Future Plans

Barclays analyst Benjamin Budish assigned a Buy rating to P10 Holdings (PX – Research Report) today and set a price target of $11.00. The company's...

P10 Holdings (PX) Gets a Buy from Barclays

In a report released today, Chris Kotowski from Oppenheimer maintained a Buy rating on P10 Holdings (PX – Research Report), with a price target of ...

Oppenheimer Reaffirms Their Buy Rating on P10 Holdings (PX)

Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more

Enhanced Community Development awarded $65M in new markets tax credits

In a report released today, Benjamin Budish from Barclays maintained a Buy rating on P10 Holdings (PX – Research Report), with a price target of $1...

In a report released today, Michael Cyprys from Morgan Stanley maintained a Hold rating on P10 Holdings (PX – Research Report), with a price target...

Comments

P10

Notizie

Ultime notizie per P10 (NYSE:PX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO